NYSE:ALife Sciences
Agilent’s USCAP 2026 Pathology Updates Deepen Oncology Diagnostics Narrative
Agilent Technologies (NYSE:A) has introduced new digital pathology advances and expanded its oncology diagnostics portfolio at the USCAP 2026 Annual Meeting.
The company is highlighting integrated, data driven tools designed to support precision oncology diagnostics and automation ready pathology workflows.
The announcements reflect Agilent’s focus on scalable lab solutions that connect instruments, software, and data across clinical pathology settings.
Agilent Technologies, trading at...